
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is a global pharmaceutical company with a diverse portfolio of products across various therapeutic areas. With its immuno-oncology platform, led by Keytruda, and a strong focus on innovation and research and development, Merck is well-positioned to capture a significant share of the growing pharmaceutical market. The recent acquisitions of Cidara Therapeutics and its promising drug candidate CD388, as well as the positive topline results from the Phase 2 CADENCE study for Winrevair, indicate potential for further growth and success. Additionally, Merck's comprehensive diversity and sustainability programs reflect its commitment to long-term and sustainable business operations.
Bears say
Merck & Co is facing multiple headwinds with their flagship drug Keytruda, including potential competition and patent expiration, which is causing concern for the company's long-term earnings growth. However, their recent data on Winrevair for Gr2 PH show promising results and potential for significant growth in this market. The stock is currently undervalued and has the potential for further re-rating as the market recognizes Merck's ability to offset Keytruda's decline with their current products and pipeline. However, the company still faces risks in their clinical trials, which could affect their future growth potential.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares